leisure time -WSS

leisure time

author：comprehensive 2025-09-30 23:38:49 - browse：6397

Truvian Health employee with a plate holding reagents used to measure commonly tested blood markers. Truvian

SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday showing that its benchtop instrument’s results are largely consistent with those generated by large central laboratories. But while the results lend support for the company’s vision of decentralized and widely available clinical testing, they also resurface questions about the value of an approach widely associated with the now defunct and notorious Bay Area startup Theranos.

In a multisite study, the company tested nearly 240 blood samples from healthy donors and chronic disease patients for dozens of blood-based measurements commonly ordered by doctors, from cholesterol to blood sugar to blood cell counts. Results from Truvian’s benchtop analytical instrument, with few exceptions, closely matched readings from devices used in large central labs and made by Swiss pharma giant Roche and Japanese firm Sysmex.

The findings were presented at the annual meeting of the American Association for Clinical Chemistry, recently rebranded as the Association for Diagnostics & Laboratory Medicine. It’s the first time Truvian has shared clinical data on its product, though they have not been published in a peer-reviewed journal. The company, which is planning additional validation studies, expects to submit for Food and Drug Administration approval of its device by the third quarter of 2024.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Doctors push to include dialysis machines in emergency stockpile

WSS

Medicare Advantage enrollment grows 7.1% to 33.4 million people

NFL doctors' conflicts of interest could endanger players, report says

Sweden knocks USA out of World Cup in penalty kicks

With heat waves through August, officials warn of health risks

FDA warns medical device makers about rise in fabricated data

New study raises questions about niacin and heart health

focus

leisure time

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Moonlake's readout produced a cash windfall. Risks remain

How CRISPR works, explained in two minutes

After affirmative action ruling, medical educators look to 'holistic review'

'Brian's Song' at 50 still offers lessons about cancer for today

Continuity nursing helped my family in our darkest PICU moments

It was time to plan for my old age. If only I could stop crying

Guidelines to prevent youth baseball injuries need more muscle

It was time to plan for my old age. If only I could stop crying

Wikipedia

A new drug could help frostbite victims avoid its ravages

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Tuberculosis patients need more than just free medication

Failure, not just success, should guide future doctors

Election results set back Medicaid expansion plans

leisure time

hotspot

focus

knowledge